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Foreword

A

T THE END OF THE ROAD in Little

Cottonwood Canyon, near Salt
Lake City, Alta is a place of
near-mythic renown among
skiers. In time it may well
assume similar status among molecular
geneticists. In December 1984, a conference
there, co-sponsored by the U.S. Department
of Energy, pondered a single question: Does
modern DNA research offer a way of detecting tiny genetic mutations—and, in particular, of observing any increase in the mutation
rate among the survivors of the Hiroshima
and Nagasaki bombings and their descendants? In short the answer was, Not yet.
But in an atmosphere of rare intellectual fertility, the seeds were sown for a project that
would make such detection possible in the
future—the Human Genome Project.
In the months that followed, much
deliberation and debate ensued. But in 1986,
the DOE took a bold and unilateral step by
announcing its Human Genome Initiative,
convinced that its mission would be well
served by a comprehensive picture of the
human genome. The immediate response
was considerable skepticism—skepticism
about the scientific community’s technological wherewithal for sequencing the genome
at a reasonable cost and about the value of
the result, even if it could be obtained economically.
Things have changed. Today, a decade
later, a worldwide effort is under way to
develop and apply the technologies needed to
completely map and sequence the human
genome, as well as the genomes of several
model organisms. Technological progress
2

has been rapid, and it is now generally agreed
that this international project will produce
the complete sequence of the human genome
by the year 2005.
And what is more important, the value
of the project also appears beyond doubt.
Genome research is revolutionizing biology
and biotechnology, and providing a vital
thrust to the increasingly broad scope of the
biological sciences. The impact that will be
felt in medicine and health care alone, once
we identify all human genes, is inestimable.
The project has already stimulated significant investment by large corporations and
prompted the creation of new companies hoping to capitalize on its profound implications.
But the DOE’s early, catalytic decision
deserves further comment. The organizers of
the DOE’s genome initiative recognized that
the information the project would generate—
both technological and genetic—would contribute not only to a new understanding of
human biology, but also to a host of practical
applications in the biotechnology industry
and in the arenas of agriculture and environmental protection. A 1987 report by a DOE
advisory committee provided some examples.
The committee foresaw that the project could
ultimately lead to the efficient production of
biomass for fuel, to improvements in the
resistence of plants to environmental stress,
and to the practical use of genetically engineered microbes to neutralize toxic wastes.
The Department thus saw far more to the
genome project than a promised tool for
assessing mutation rates. For example,
understanding the human genome will have
an enormous impact on our ability to assess,
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individual by individual, the risk posed by
environmental exposures to toxic agents. We
know that genetic differences make some of
us more susceptible, and others more resistant, to such agents. Far more work must be
done before we understand the genetic basis
of such variability, but this knowledge will
directly address the DOE’s long-term mission to understand the effects of low-level
exposures to radiation and other energyrelated agents—especially the effects of
such exposure on cancer risk. And the
genome project is a long stride toward such
knowledge.
The Human Genome Project has other
implications for the DOE as well. In 1994,
taking advantage of new capabilities developed by the genome project, the DOE formulated the Microbial Genome Initiative to
sequence the genomes of bacteria of likely
interest in the areas of energy production and
use, environmental remediation and waste
reduction, and industrial processing. As a
result of this initiative, we already have complete sequences for two microbes that live
under extreme conditions of temperature and
pressure. Structural studies are under way to
learn what is unique about the proteins of
these organisms—the aim being ultimately to
engineer these microbes and their enzymes
for such practical purposes as waste control
and environmental cleanup. (DOE-funded
genetic engineering of a thermostable DNA
polymerase has already produced an enzyme
that has captured a large share of the severalhundred-million-dollar DNA polymerase
market.)
And other little-studied microbes hint
at even more intriguing possibilities. For
instance, Deinococcus radiodurans is a species
that prospers even when exposed to huge
doses of ionizing radiation. This microbe has
an amazing ability to repair radiationinduced damage to its DNA. Its genome is
currently being sequenced with DOE support, with the hope of understanding and
ultimately taking practical advantage of its
unusual capabilities. For example, it might
be possible to insert foreign DNA into this
microbe that allows it to digest toxic organic

components found in highly radioactive
waste, thus simplifying the task of further
cleanup. Another approach might be to
introduce metal-binding proteins onto the
microbe’s surface that would scavenge highly
radioactive isotopes out of solution.
Biotechnology, fueled in part by
insights reaped from the genome project, will
also play a significant role in improving
the use of fossil-based resources. Increased
energy demands, projected over the next 50
years, require strategies to circumvent the
many problems associated with today’s
dominant energy systems. Biotechnology
promises to help address these needs by
upgrading the fuel value of our current energy resources and by providing new means for
the bioconversion of raw materials to refined
products—not to mention offering the
possibility of entirely new biomass-based
energy sources.
We have thus seen only the dawn of a
biological revolution. The practical and economic applications of biology are destined for
dramatic growth. Health-related biotechnology is already a multibillion-dollar success
story—and is still far from reaching its potential. Other applications of biotechnology are
likely to beget similar successes in the coming
decades. Among these applications are several of great importance to the DOE. We can
look to improvements in waste control and an
exciting era of environmental bioremediation; we will see new approaches to improving energy efficiency; and we can even hope
for dramatic strides toward meeting the fuel
demands of the future. The insights, the
technologies, and the infrastructure that are
already emerging from the genome project,
together with advances in fields such as computational and structural biology, are among
our most important tools in addressing these
national needs.

Aristides A. N. Patrinos
Director, Human Genome Project
U.S. Department of Energy
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The Genome Project–
Why the DOE?
A

B O L D

T

B U T

L O G I C A L

S T E P

HE BIOSCIENCES RESEARCH community is now embarked on a
program whose boldness, even
audacity, has prompted comparisons with such visionary efforts
as the Apollo space program and the
Manhattan project. That life scientists
should conceive such an ambitious project is
not remarkable; what is surprising—at least
at first blush—is that the project should trace
its roots to the Department of Energy.
For close to a half-century, the DOE
and its governmental predecessors have been
charged with pursuing a deeper understanding of the potential health
risks posed by energy use
and by energy-production
In 1986
technologies—with special
the DOE
interest focused on the
effects of radiation on
was the first
humans. Indeed, it is fair to
federal agency
say that most of what we
to announce
know today about radiological health hazards stems
an initiative
from studies supported by
to pursue a
these government agencies.
Among these investigations
detailed underare long-standing studies of
standing of the
the survivors of the atomic
bombings of Hiroshima and
human genome.
Nagasaki, as well as any
number of experimental
studies using animals, cells
in culture, and nonliving systems. Much has
been learned, especially about the consequences of exposure to high doses of radiation. On the other hand, many questions
remain unanswered; in particular, we have
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much to learn about how low doses
produce their insidious effects. When present
merely in low but significant amounts, toxic
agents such as radiation or mutagenic chemicals work their mischief in the most subtle
ways, altering only slightly the genetic
instructions in our cells. The consequences
can be heritable mutations too slight to produce discernible effects in a generation or two
but, in their persistence and irreversibility, deeply troublesome nonetheless.
Until recently, science offered little
hope for detecting at first hand these
tiny changes to the DNA that encodes our
genetic program. Needed was a tool that
could detect a change in one “word” of
the program, among perhaps a hundred
million. Then, in 1984, at a meeting convened
jointly by the DOE and the International
Commission for Protection Against Environmental Mutagens and Carcinogens, the question was first seriously asked: Can we, should
we, sequence the human genome? That is,
can we develop the technology to obtain a
word-by-word copy of the entire genetic
script for an “average” human being, and thus
to establish a benchmark for detecting the
elusive mutagenic effects of radiation and
cancer-causing toxins? Answering such a
question was not simple. Workshops were
convened in 1985 and 1986; the issue was
studied by a DOE advisory group, by the
Congressional Office of Technology Assessment, and by the National Academy of
Sciences; and the matter was debated publicly
and privately among biologists themselves. In
the end, however, a consensus emerged that
we should make a start.

The Genome Project — Why the DOE?

Adding impetus to the DOE’s earliest
interest in the human genome was the
Department’s stewardship of the national
laboratories, with their demonstrated ability
to conduct large multidisciplinary projects—
just the sort of effort that would be needed
to develop and implement the technological
know-how needed for the Human Genome
Project. Biological research programs already in place at the national labs benefited
from the contributions of engineers, physicists, chemists, computer scientists, and
mathematicians, working together in teams.
Thus, with the infrastructure in place and
with a particular interest in the ultimate
results, the Department of Energy, in 1986,
was the first federal agency to announce and
to fund an initiative to pursue a detailed
understanding of the human genome.
Of course, interest was not restricted to
the DOE. Workshops had also been sponsored by the National Institutes of Health,
the Cold Spring Harbor Laboratory, and the
Howard Hughes Medical Institute. In 1988
the NIH joined in the pursuit, and in the fall
of that year, the DOE and the NIH signed a
memorandum of understanding that laid the
foundation for a concerted interagency effort.
The basis for this community-wide excitement is not hard to comprehend. The first
impulse behind the DOE’s commitment was
only one of many reasons for coveting a
deeper insight into the human genetic script.
Defective genes directly account for an estimated 4000 hereditary human diseases—maladies such as Huntington disease and cystic
fibrosis. In some such cases, a single misplaced letter among three billion can have
lethal consequences. For most of us, though,
even greater interest focuses on the far more
common ailments in which altered genes
influence but do not prescribe. Heart disease, many cancers, and some psychiatric disorders, for example, can emerge from complicated interplays of environmental factors and
genetic misinformation.
The first steps in the Human Genome
Project are to develop the needed technologies, then to “map” and “sequence” the

genome. But in a sense, these well-publicized efforts aim only to provide the raw
material for the next, longer strides. The ultimate goal is to exploit those resources for a
truly profound molecular-level understanding of how we develop from embryo to adult,
what makes us work, and what causes things
to go wrong. The benefits to be reaped
stretch the imagination. In the offing is a
new era of molecular medicine characterized
not by treating symptoms, but rather by
looking to the deepest causes of disease.
Rapid and more accurate diagnostic tests will
make possible earlier treatment for countless
maladies. Even more promising, insights
into genetic susceptibilities to disease and to
environmental insults, coupled with preventive therapies, will thwart some diseases altogether. New, highly targeted pharmaceuticals, not just for heritable diseases, but for
communicable ailments as well, will attack
diseases at their molecular foundations. And
even gene therapy will become possible, in
some cases actually “fixing” genetic errors.
All of this in addition to a new intellectual
perspective on who we are and where we
came from.
The Department of Energy is proud to
be playing a central role in propelling us
toward these noble goals.
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Introducing the
Human Genome
T H E

R E C I P E

F

F O R

L I F E

of the
world’s five and a half billion people, full of creativity and contradictions, the machinery of every
human mind and body is built
and run with fewer than 100,000 kinds of
protein molecules. And for each of these proteins, we can imagine a single corresponding
gene (though there is sometimes some redundancy) whose job it is to ensure an adequate
and timely supply. In a material sense, then,
all of the subtlety of our species, all of our art
and science, is ultimately accounted for by a
surprisingly small set of discrete genetic
instructions. More surprising still, the differences between two unrelated individuals,
between the man next door and Mozart, may
reflect a mere handful of differences in their
genomic recipes—perhaps one altered word
in five hundred. We are far more alike than
we are different. At the same time, there is
room for near-infinite variety.
It is no overstatement to say that to
decode our 100,000 genes in some fundamental way would be an epochal step toward
unraveling the manifold mysteries of life.
SOME
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OR ALL THE DIVERSITY

DEFINITIONS

The human genome is the full complement of genetic material in a human cell.
(Despite five and a half billion variations on a
theme, the differences from one genome to
the next are minute; hence, we hear about the
human genome—as if there were only one.)
The genome, in turn, is distributed among 23
sets of chromosomes, which, in each of us, have
been replicated and re-replicated since the

fusion of sperm and egg that marked our conception. The source of our personal uniqueness, our full genome, is therefore preserved
in each of our body’s several trillion cells. At
a more basic level, the genome is DNA,
deoxyribonucleic acid, a natural polymer
built up of repeating nucleotides, each consisting of a simple sugar, a phosphate group, and
one of four nitrogenous bases. The hierarchy
of structure from chromosome to nucleotide
is shown in Figure 1. In the chromosomes,
two DNA strands are twisted together into
an entwined spiral—the famous double
helix—held together by weak bonds between
complementary bases, adenine (A) in one
strand to thymine (T) in the other, and cytosine to guanine (C–G). In the language of
molecular genetics, each of these linkages
constitutes a base pair. All told, if we count
only one of each pair of chromosomes, the
human genome comprises about three billion
base pairs.
The specificity of these base-pair linkages underlies all that is wonderful about
DNA. First, replication becomes straightforward. Unzipping the double helix provides
unambiguous templates for the synthesis of
daughter molecules: One helix begets two
with near-perfect fidelity. Second, by a similar template-based process, depicted in
Figure 2, a means is also available for producing a DNA-like messenger to the cell
cytoplasm. There, this messenger RNA, the
faithful complement of a particular DNA
segment, directs the synthesis of a particular
protein. Many subtleties are entailed in the
synthesis of proteins, but in a schematic
sense, the process is elegantly simple.

Introducing the Human Genome

FIGURE 1. SOME DNA DETAILS. Apart from reproductive gametes, each cell of the
human body contains 23 pairs of chromosomes, each a packet of compressed and entwined DNA.
Every strand of the DNA is a huge natural polymer of repeating nucleotide units, each of which
comprises a phosphate group, a sugar (deoxyribose), and a base (either adenine, thymine, cytosine,
or guanine). Every strand thus embodies a code of four characters (A’s, T’s, C’s, and G’s), the recipe
for the machinery of human life. In its normal state, DNA takes the form of a highly regular doublestranded helix, the strands of which are linked by hydrogen bonds between adenine and thymine (A–T)
and between cytosine and guanine (C–G). Each such linkage is said to constitute a base pair; some
three billion base pairs constitute the human genome. It is the specificity of these base-pair linkages
that underlies the mechanism of DNA replication illustrated here. Each strand of the double helix
serves as a template for the synthesis of a new strand, the nucleotide sequence of which is strictly
determined. Replication thus produces twin daughter helices, each an exact replica of its sole parent.
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Every protein is made up of one or
more polypeptide chains, each a series of
(typically) several hundred molecules known
as amino acids, linked by so-called peptide
bonds. Remarkably, only 20 different kinds
of amino acids suffice as the building blocks
for all human proteins. The synthesis of a
protein chain, then, is simply a matter of
specifying a particular sequence of amino
acids. This is the role of the messenger RNA.
(The same nitrogenous bases are at work in

RNA as in DNA, except that uracil takes the
place of the DNA base thymine.) Each linear sequence of three bases (both in RNA
and in DNA) corresponds uniquely to a
single amino acid. The RNA sequence AAU
thus dictates that the amino acid asparagine
should be added to a polypeptide chain, GCA
specifies alanine—and so on. A segment of
the chromosomal DNA that directs the synthesis of a single type of protein constitutes
a single gene.
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A

PLAN OF ACTION

In 1990 the Department of Energy and
the National Institutes of Health developed a
joint research plan for their genome programs, outlining specific goals for the ensuing five years. Three years later, emboldened
by progress that was on track or even ahead
of schedule, the two agencies put forth an
updated five-year plan. Improvements in
technology, together with the experience of
three years, allowed an even more ambitious
prospect.
In broad terms, the revised plan
includes goals for genetic and physical
mapping of the genome, DNA sequencing,
identifying and locating
genes, and pursuing further
developments in technology
and informatics. To a large
The plan includes
extent, the following pages
goals for genetic
are devoted to a discussion
of just what these goals
and physical
mean, and what part the
mapping, DNA
DOE is playing in pursuing
them. In addition, the plan
sequencing,
emphasizes the continuing
identifying and
importance of the ethical,
locating genes,
legal, and social implications
of genome research, and it
and pursuing furunderscores the critical roles
ther developments
of scientific training, technology transfer, and public
in technology
access to research data and
and informatics.
materials. Most of the goals
focus on the human genome,
but the importance of continuing research on widely
studied “model organisms” is also explicitly
recognized.
Among the scientific goals of human
genome research, several are especially
notable, as they provide clear milestones for
future progress. In reciting them, however, it
is important to note an underlying assumption of adequate research support. Such support is obviously crucial if the joint plan is to
succeed. Some of the central goals for
1993–98 follow:
8

◆

◆

◆

◆

◆

◆

Complete a genetic linkage map at a resolution of two to five centimorgans by
1995—As discussed on page 10, this goal
was far surpassed by the fall of 1994.
Complete a physical map at a resolution
of 100 kilobases by 1998—This implies
a genome map with 30,000 “signposts,”
separated by an average of 100,000
base pairs. Further, each signpost will be
a sequence-tagged site, a stretch of DNA
with a unique and well-defined DNA
sequence. Such a map will greatly facilitate “production sequencing” of the entire
genome. By the end of 1995, molecular
biologists were halfway to this goal: A
physical map was announced with 15,000
sequence-tagged signposts. Physical mapping is discussed on pages 10–16.
By 1998 develop the capacity to sequence
50 million base pairs per year in long
continuous segments—Adequate fiscal
investment and continuing progress
beyond 1998 should then produce a
fully sequenced human genome by the
year 2005 or earlier. Sequencing is the
subject of pages 16–26.
Develop efficient methods for identifying
and locating known genes on physical
maps or sequenced DNA—The goals
here are less quantifiable, but the aim is
central to the Human Genome Project: to
home in on and ultimately to understand
the most important human genes, namely,
the ones responsible for serious diseases
and those crucial for healthy development
and normal functions.
Pursue technological developments in
areas such as automation and robotics—
A continuing emphasis on technological
advance is critical. Innovative technologies, such as those described on pages
27–30, are the necessary underpinnings of
future large-scale sequencing efforts.
Continue the development of database
tools and software for managing and
interpreting genome data—This is the
area of informatics, discussed on pages
30–31. The challenge is not so much the
volume of data, but rather the need to
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FIGURE 2. FROM GENES TO PROTEINS. In the cell nucleus, RNA is produced by transcription, in much the same way

that DNA replicates itself. RNA, however, substitutes the sugar ribose for deoxyribose and the base uracil for thymine, and is usually
single-stranded. One form of RNA, messenger RNA or mRNA, conveys the DNA recipe for protein synthesis to the cell cytoplasm.
There, bound temporarily to a cytoplasmic particle known as a ribosome, each three-base codon of the mRNA links to a specific form of
transfer RNA (tRNA) containing the complementary three-base sequence. This tRNA, in turn, transfers a single amino acid to a growing
protein chain. Each codon thus unambiguously directs the addition of one amino acid to the protein. On the other hand, the same amino
acid can be added by different codons; in this illustration, the mRNA sequences GCA and GCC are both specifying the addition of the
amino acid alanine (Ala).

◆

mount a system compatible with researchers around the world, and one that
will allow scientists to contribute new data
and to freely interrogate the existing databases. The ultimate measure of success
will be the ease with which biologists can
fruitfully use the information produced by
the genome project.
Continue to explore the ethical, legal,
and social implications of genome
research—Much emphasis continues to be
placed on issues of privacy and the fair use
of genetic information. New goals focus
on defining additional pertinent issues and

developing policy responses to them, disseminating policy options regarding
genetic testing services, fostering greater
acceptance of human genetic variation,
and enhancing public and professional
education that is sensitive to sociocultural
and psychological issues. This side of
the genome project is discussed on
pages 32–33.
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Exploring the
Genomic Landscape
M A P P I N G

O

T H E

T E R R A I N

of
the Human Genome Project
is to produce a detailed “map”
of the human genome. But,
just as there are topographic
maps and political maps and highway maps of
the United States, so there are different kinds
of genome maps, the variety of which
is suggested in Figure 3. One type, a genetic
linkage map, is based on careful analyses
of human inheritance patterns. It indicates
for each chromosome the
whereabouts of genes or
other “heritable markers,”
Just as there
with distances measured in
are topographic
centimorgans, a measure of
recombination frequency.
maps and
During the formation of
political maps
sperm and egg cells, a process
of genetic recombination—or
and highway
“crossing over”—occurs in
maps, so there
which pieces of genetic material are swapped between
are different
paired chromosomes. This
kinds of
process of chromosomal
genome maps.
scrambling accounts for the
differences invariably seen
even in siblings (apart from
identical twins). Logically, the closer two
genes are to each other on a single chromosome, the less likely they are to get split up
during genetic recombination. When they
are close enough that the chances of being
separated are only one in a hundred, they
are said to be separated by a distance of
one centimorgan.
10

NE OF THE CENTRAL GOALS

The role of human pedigrees now
becomes clear. By studying family trees and
tracing the inheritance of diseases and physical traits, or even unique segments of DNA
identifiable only in the laboratory, geneticists
can begin to pin down the relative positions
of these genetic markers. By the end of 1994,
a comprehensive map was available that
included more than 5800 such markers,
including genes implicated in cystic fibrosis,
myotonic dystrophy, Huntington disease,
Tay-Sachs disease, several cancers, and many
other maladies. The average gap between
markers was about 0.7 centimorgan.
Other maps are known as physical maps,
so called because the distances between features are measured not in genetic terms, but
in “real” physical units, typically, numbers of
base pairs. A close analogy can thus be
drawn between physical maps and the road
maps familiar to us all. Indeed, the analogy
can be extended further. Just as small-scale
road maps may show only large cities and
indicate distances only between major features, so a low-resolution physical map
includes only a relative sprinkling of chromosomal landmarks. A well-known low-resolution physical map, for example, is the familiar
chromosomal map, showing the distinctive
staining patterns that can be seen in the light
microscope. Further, by a process known as
in situ hybridization, specific segments of DNA
can be targeted in intact chromosomes by
using complementary strands synthesized in
the laboratory. These laboratory-made
“probes” carry a fluorescent or radioactive

Myotonic dystrophy (DM)

Hemolytic anemia (GPI)
Malignant hyperthermia (RYR1)

Pseudoachondroplasia (COMP)

Insulin-resistant
diabetes (INSR)
Familial
hypercholesterolemia (LDLR)
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FIGURE 3. GENOMIC GEOGRAPHY. The human genome can be
mapped in a number of ways. The familiar and reproducible banding pattern of
the chromosomes constitutes one kind of physical map, and in many cases, the
positions of genes or other heritable markers have been localized to one band or
another. More useful are genetic linkage maps, on which the relative positions of
markers have been established by studying how frequently the markers are separated during a natural process of chromosomal shuffling called genetic recombination. The cryptically coded ordered markers near the top of this figure are physically mapped to specific regions of chromosome 19; some of them also constitute

a low-resolution genetic linkage map. (Hundreds of genes and other markers have
been mapped on chromosome 19; only a few are indicated here. See Figure 5 for
a display of mapped genes.) A higher-resolution physical map might describe, as
shown here, the cutting sites (the short vertical lines) for certain DNA-cleaving
enzymes. The overlapping fragments that allow such a map to be constructed are
then the resources for obtaining the ultimate physical map, the base-pair sequence
for the human genome. At the bottom of this figure is an example of output from
an automatic sequencing machine.
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FIGURE 4. FISHING
FOR GENES. Fluorescence

in situ hybridization (FISH)
probes are strands of DNA that
have been labeled with
fluorescent dye molecules.
The probes bind uniquely to
complementary strands of chromosomal DNA, thus pinpointing
the positions of target DNA
sequences. In this example, one
probe, whose fluorescence
signal is shown in red, binds
specifically to a gene (DSRAD)
that codes for an important
RNA-modifying enzyme. A second probe, whose signal
appears in green, binds to a
marker sequence whose location
was already known. The previously unknown location of the
DSRAD gene was thus accurately mapped to a narrow
region on the long arm of
chromosome 1.

label, which can then be detected and thus
pinpointed on a specific region of the chromosome. Figure 4 shows some results of
fluorescence in situ hybridization (FISH).
Of particular interest are probes known as
cDNA (for complementary DNA), which are
synthesized by using molecules of messenger
RNA as templates. These molecules of
cDNA thus hybridize to “expressed” chromosomal regions—regions that directly dictate
the synthesis of proteins. However, a physical map that depended only on in situ
hybridization would be a fairly coarse one.
Fluorescent tags on intact chromosomes cannot be resolved into separate spots unless
they are two to five million base pairs apart.
Fortunately, means are also available to
produce physical maps of much higher resolution—analogous to large-scale county maps
that show every village and farm road, and
indicate distances at a similar level of detail.
Just such a detailed physical map is one that
emerges from the use of restriction enzymes—
DNA-cleaving enzymes that serve as highly
selective microscopic scalpels (see “Tools of
12

the Trade,” pages 17–19). A typical restriction enzyme known as EcoRI, for example,
recognizes the DNA sequence GAATTC and
selectively cuts the double helix at that site.
One use of these handy tools involves cutting
up a selected chromosome into small pieces,
then cloning and ordering the resulting fragments. The cloning, or copying, process is a
product of recombinant DNA technology, in
which the natural reproductive machinery of
a “host” organism—a bacterium or a yeast,
for example—replicates a “parasitic” fragment of human DNA, thus producing the
multiple copies needed for further study (see
“Tools of the Trade”). By cloning enough
such fragments, each overlapping the next
and together spanning long segments (or
even the entire length) of the chromosome,
workers can eventually produce an ordered
library of clones. Each contiguous block of
ordered clones is known as a contig (a small
one is shown in Figure 3), and the resulting
map is a contig map. If a gene can be localized to a single fragment within a contig map,
its physical location is thereby accurately
pinned down. Further, these conveniently
sized clones become resources for further
studies by researchers around the world—
as well as the natural starting points for
systematic sequencing efforts.
TWO GIANT STEPS:
CHROMOSOMES 16

AND

19

One of the signal achievements of the
DOE genome effort so far is the successful
physical mapping of chromosomes 16 and 19.
The high-resolution chromosome 19 map,
constructed at the Lawrence Livermore
National Laboratory, is based on restriction
fragments cloned in cosmids, synthetic cloning
“vectors” modeled after bacteria-infecting
viruses known as bacteriophages. Like a
phage, a cosmid hijacks the cellular machinery of a bacterium to mass-produce its own
genetic material, together with any “foreign”
human DNA that has been smuggled into it.
The foundation of the chromosome 19 map is
a large set of cosmid contigs that were assembled by automated analysis of overlapping
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FIGURE 5. AN EMERGING GENE MAP. More than 250 genes have

already been mapped to chromosome 19. Those listed on the lower half of this
illustration have been assigned to specific cosmids and (except for those marked
with asterisks) have been ordered on the Livermore physical map. Their positions
are therefore known with far greater accuracy than shown here. The genes
listed above the chromosome have been mapped to larger regions of the chromo-
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some—or merely localized to chromosome 19 generally—and have not yet been
assigned to cosmids in the Livermore database. The text mentions several of the
most important genes mapped so far. Others include INSR, which codes for an
insulin receptor and is involved in adult-onset diabetes; LDLR, a gene for a lowdensity lipoprotein receptor involved in hypercholesterolemia; and ERCC2, a DNA
repair gene implicated in one form of xeroderma pigmentosum.
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but unordered restriction fragments. These
contigs span an estimated 54 million base
pairs, more than 95 percent of the chromosome, excluding the centromere.
Most of the contigs have been mapped
by fluorescence in situ hybridization to visible chromosomal bands. Further, more than
200 cosmids have been more accurately
ordered along the chromosome by a high-resolution FISH technique in which the distances between cosmids are determined with
a resolution of about 50,000 base pairs. This
ordered FISH map, with cosmid reference
points separated by an average of 230,000
base pairs, provides the essential framework
to which other cosmid contigs can be
anchored. Moreover, the EcoRI restriction
sites have been mapped on more than 45 million base pairs of the overall cosmid map.
Over 450 genes and genetic markers have
also been localized on this map, of which
nearly 300 have been incorporated into the
ordered map. Figure 5 shows the locations of
the mapped genes. Among these genes is the
one responsible for the most common form of
adult muscular dystrophy (DM), which was
identified in 1992 by an international consortium that included Livermore scientists.
A second important disease gene (COMP),
responsible for a form of dwarfism known
as pseudoachondroplasia, has also been identified. And yet another gene, one linked to a
form of congenital kidney disease, has been
localized to a single contig spanning one
million base pairs, but has not yet been
precisely pinpointed. About 2000 other
genes are likely to be found eventually on
chromosome 19.
In a similar effort, the Los Alamos
National Laboratory Center for Human
Genome Studies has completed a highly integrated map of chromosome 16, a chromosome that contains genes linked to blood disorders, a second form of kidney disease,
leukemia, and breast and prostate cancers.
A readable display of this integrated map
covers a sheet of paper more than 15 feet
long; a portion of it, much reduced and
showing only some of its central features, is
reproduced here as Figure 6. The framework
14

for the Los Alamos effort is yet another kind
of map, a “cytogenetic breakpoint map”
based on 78 lines of cultured cells, each a
hybrid that contains mouse chromosomes
and a fragment of human chromosome 16.
Natural breakpoints in chromosome 16 are
thus identified, leading to a breakpoint map
that divides the chromosome into segments
whose lengths average 1.1 million base pairs.
Anchored to this framework are a low-resolution contig map based on YAC clones and a
high-resolution contig map based largely on
cosmids (for more on YACs, yeast artificial
chromosomes, see “Tools of the Trade,” pages
17–19). The low-resolution map, comprising
700 YACs from a library constructed by the
Centre d’Etude du Polymorphisme Humain
(CEPH), provides practically complete coverage of the chromosome, except the highly
repetitive DNA in the centromere region.
The high-resolution map comprises some
4000 cosmid clones, assembled into about
500 contigs covering 60 percent of the chromosome. In addition, it includes 250 smaller
YAC clones that have been merged with the
cosmid contig map. The cosmid contig map
FIGURE 6. MAPPING CHROMOSOME 16.

This much-reduced physical map of the short arm of human
chromosome 16 summarizes the progress made at Los Alamos
toward a complete map of the chromosome. A legible, fully
detailed map of the chromosome is more than 15 feet long;
only a few features of the map can be described here. Just
below the schematic chromosome, the black arrowheads and
the vertical lines extending the full length of the page signify
“breakpoints” and indicate the portions of the chromosome
maintained in separate cell cultures. The cultured portions typically extend from a breakpoint to one end of the chromosome.
These breakpoints establish the framework for the Los Alamos
mapping effort. Within this framework, some 700 megaYACs
(shown in black) provide low-resolution coverage for essentially the entire chromosome. Smaller flow-sorted YACs (light
blue, red, and black), together with about 4000 cosmids,
assembled into about 500 cosmid contigs (blue and red),
establish high-resolution coverage for 60% of the chromosome. Sequence-tagged sites (STSs) are shown as colored vertical lines above the megaYACs, and genes (green) and genetic
markers (pink) that have been localized only to the breakpoint
map are shown near the bottom. Also shown are cloned and
uncloned disease regions, as well as those markers whose
analogs have been identified among mouse chromosomes
(see “The Mighty Mouse,” pages 24–25).
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is an especially important step forward, since
it is a “sequence-ready” map. It is based
on bacterial clones that are ideal substrates for DNA sequencing, and further, these clones have been restriction
mapped to allow identification
of a minimum set of overlapping clones for a large-scale
These maps are
sequencing effort.
The high- and low-resolumere stepping
tion maps have been tied
stones to the
together by sequence-tagged
sites (STSs), short but unique
string of three
stretches of DNA sequence.
billion characters –
They have also been integrated
into the breakpoint map, and
A’s, T’s, C’s,
with genetic maps developed
and G’s – that
at the Adelaide Children’s
Hospital and by CEPH. The
defines our
integrated map also includes a
species.
transcription map of 1000
sequenced exons (expressed
fragments of genes) and more
than 600 other markers developed at other
laboratories around the world.
G E T T I N G D O W N T O D E TA I L S :
SEQUENCING THE GENOME
Ultimately, though, these physical maps
and the clones they point to are mere stepping stones to the most visible goal of the
genome project, the string of three billion
characters—A’s, T’s, C’s, and G’s—representing the sequence of base pairs that defines
our species. Included, of course, would be
the sequence for every gene, as well as the
sequences for stretches of DNA whose functions we don’t yet know (but which may be
involved in such little-understood processes
as orchestrating gene expression in different
parts of our bodies, at different times of our
lives). Should anyone undertake to print it
all out, the result would fill several hundred
volumes the size of a big-city phone book.
Only the barest start has been made in
taking this dramatic step in the Human
Genome Project. Several hundred million
base pairs have been sequenced and archived
in databases, but the great majority of these
16

are from short “sequence tags” on cloned
fragments. Only about 30 million base pairs
of human DNA (roughly one percent of
the total) have been sequenced in longer
stretches, the longest being about 685,000
base pairs long. Even more daunting is the
realization that we will eventually need to
sequence many parts of the genome many
times, thus to reveal differences that indicate
various forms of the same gene.
Hence, as with so many human enterprises, the challenge of sequencing the
genome is largely one of doing the job
cheaper and faster. At the beginning of the
project, the cost of sequencing a single base
pair was between $2 and $10, and one
researcher could produce between 20,000
and 50,000 base pairs of continuous, accurate
sequence in a year. Sequencing the genome
by the year 2005 would therefore likely cost
$10–20 billion and require a dedicated cadre
of at least 5000 workers. Clearly, a major
effort in technology development was called
for—an effort that would drive the cost well
below $1 per base pair and that would allow
automation of the sequencing process. From
the beginning, therefore, the DOE has
emphasized programs to pave the way for
expeditious and economical sequencing
efforts—programs to develop new technologies, including new cloning vectors, and to
establish suitable resources for sequencing,
including clone libraries and libraries of
expressed sequences.
Efforts to develop new cloning vectors
have been especially productive. YACs
remain a classic tool for cloning large
fragments of human DNA, but they are not
perfect. Some regions of the genome, for
example, resist cloning in YACs, and others
are prone to rearrangement. New vectors
such as bacterial artificial chromosomes
(BACs), P1 phages, and P1-derived artificial
cloning systems (PACs) have thus been
devised to address these problems. These
new approaches are critical for ensuring
that the entire genome can be faithfully
represented in clone libraries, without the
danger of deletions, rearrangements, or
spurious insertions.
Continues on p. 20
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O

ver the next decade, as molecular
biologists tackle the task of
sequencing the human genome
on a massive scale, any number
of innovations can be expected in

mapping and sequencing technologies. But several
of the central tools of molecular genetics are likely to
stay with us—much improved perhaps, but not fundamentally different. One such tool is the class of
DNA-cutting proteins known as restriction enzymes.
These enzymes, the first of which were discovered in

Chromosomal DNA
digested with EcoRI
restriction enzyme

the late 1960s, cleave double-stranded DNA molecules at specific recognition sites, usually four or six
nucleotides long. For example, a restriction enzyme
called EcoRI recognizes the single-strand sequence
GAATTC and invariably cuts the double helix as

A A
G
C

T

T

Cutting C
G
T T site
A

A

shown in the illustration on the right.
When digested with a particular restriction
enzyme, then, identical segments of human DNA
yield identical sets of restriction fragments. On the

Restriction fragments

other hand, DNA from the same genomic region of
two different people, with their subtly different
genomic sequences, can yield dissimilar sets of fragments, which then produce different patterns when
sorted according to size.
This leads directly to discussion of a second
essential tool of modern molecular genetics, gel

electrophoresis, for it is by electrophoresis that DNA
fragments of different sizes are most often separated.
In classical gel electrophoresis, electrically charged
macromolecules are caused to migrate through a
polymeric gel under the influence of an imposed sta-

Gel electrophoresis

tic electric field. In time the molecules sort themselves by size, since the smaller ones move more
rapidly through the gel than do larger ones. In 1984

DIGESTING DNA. Isolated from various bacteria, restriction enzymes serve as

a further advance was made with the invention of

microscopic scalpels that cut DNA molecules at specific sites. The enzyme EcoRI, for
example, cuts double-stranded DNA only where it finds the sequence GAATTC. The
resulting fragments can then be separated by gel electrophoresis. The electrophoresis
pattern itself can be of interest, since variations in the pattern from a given chromosomal region can sometimes be associated with variations in genetic traits, including
susceptibilities to certain diseases. Knowledge of the cutting sites also yields a kind
of physical map known as a restriction map.

pulsed-field gel electrophoresis, in which the
strength and direction of the applied field is varied
rapidly, thus allowing DNA strands of more than
50,000 base pairs to be separated.
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A third necessary tool is some means of

bling the amount of DNA originally present. Again

DNA “amplification.” The classic example is the

and again, the strands can be separated and the

cloning vector, which may be circular DNA mole-

polymerase reaction repeated—so effectively, in

cules derived from bacteria or from bacteriophages

fact, that DNA can be amplified by 100,000-fold in

(viruslike parasites of bacteria), or artificial chro-

less than three hours. As with cloning vectors, the

mosomes constructed from yeast

result is a large collection of copies of the original

or bacterial genomic DNA. The

DNA fragment.

characteristic all these vectors

When a clone library can be ordered—that

share is that fragments of “foreign”

is, when the relative positions on the human chro-

DNA can be inserted into them,

mosomes can be established for all the fragments—

whereby the inserted DNA is

one then has the perfect resource for achieving the

replicated along with the rest of

project’s central goal, sequencing the human

the vector as the host reproduces

genome. How the sequencing is actually done can

itself. A yeast artificial chromo-

be illustrated by the most popular method in cur-

some, or YAC, for instance, is

rent use, the Sanger procedure, which is depicted

constructed by assembling the

schematically on the facing page. The first step is

essential functional parts of a nat-

to prime each identical DNA strand in a prepara-

ural yeast chromosome—DNA

tion of cloned fragments. The preparation is then

sequences that initiate replication,

divided into four portions, each of which contains

sequences that mark the ends of

a

the chromosomes, and sequences

together with the usual reagents for replication. In

required for chromosome separa-

one batch, the replication reaction always pro-

tion during cell division—then splicing in a frag-

duces complementary strands that end with A; in

ment of human DNA. This engineered chromo-

another, with G; and so on. Gel electrophoresis is

some is then reinserted into a yeast cell, which

used to sift the resulting products according to size,

reproduces the YAC during cell division, as if it

allowing one to infer the exact nucleotide

were part of the yeast’s normal complement of

sequence for the original DNA strand. ❖

One of the
important
achievements of
the project has
been to establish
several libraries of
cloned fragments
covering the
entire human
genome.

different

reaction-terminating

nucleotide,

chromosomes. The result is a colony of yeast cells,
each containing a copy, or clone, of the same

SPELLING OUT THE ANSWER. In the much-

fragment of human DNA. One of the important

automated Sanger sequencing method, the single-stranded DNA
to be sequenced is “primed” for replication with a short complementary strand at one end. This preparation is then divided
into four batches, and each is treated with a different replication-halting nucleotide (depicted here with a diamond shape),
together with the four “usual” nucleotides. Each replication
reaction then proceeds until a reaction-terminating nucleotide is
incorporated into the growing strand, whereupon replication
stops. Thus, the “C” reaction produces new strands that
terminate at positions corresponding to the G’s in the strand
being sequenced. (Note that when long strands are being
sequenced the concentration of the reaction-terminating
nucleotide must be carefully chosen, so that a “normal” C is
usually paired with a G; otherwise, replication would typically
stop with the first or second G.) Gel electrophoresis—one
lane per reaction mixture—is then used to separate the replication products, from which the sequence of the original single
strand can be inferred.

achievements of the Human Genome Project has
been to establish several libraries of such cloned
fragments, using several different vectors (bacterial
artificial chromosomes, P1 phages, and P1-derived
cloning systems), that cover the entire human
genome.
Another way of amplifying DNA is the poly-

merase chain reaction, or PCR. This enzymatic
replication technique requires that initiators, or
PCR primers, be attached as short complementary
strands at the ends of the separated DNA fragments
to be replicated. An enzyme then completes the
synthesis of the complementary strands, thus dou18
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Marked progress is also evident in the
development of sequencing technologies,
though all of those in widespread current use
are still based on methods developed in 1977
by Allan Maxam and Walter Gilbert and by
Frederick Sanger and his coworkers (see
“Tools of the Trade,” pages 17–19). Both of
these methods rely on gel-based electrophoresis systems to separate DNA fragments, and recent advances in commercial
systems include increasing the number of gel
lanes, decreasing run times, and enhancing
the accuracy of base identification. As a
result of such improvements, a standard
sequencing machine can now turn out raw,
unverified sequences of 50,000 to 75,000
bases per day.
Equally important to the sequencing
goals of the genome project is a rational
system for organizing and distributing the
material to be sequenced. The DOE’s commitment to such resources dates back to
1984, when it organized
the National Laboratory
Gene Library Project.
Advances
Based on cell- and chromohave brought
some-sorting technologies
developed at Livermore
much nearer
and Los Alamos, libraries
the day when
of clones were established
for each of the human
“production
chromosomes, and the indisequencing”
vidual clones are widely
can begin.
available for mapping and
for isolating genes. These
clones were invaluable in
such notable “gene hunts” as the successful
searches for the cystic fibrosis and
Huntington disease genes. More recently, as
more efficient vectors have become available,
complete human DNA libraries have been
established using BACs, PACs, and YACs.
Another critical resource is being
assembled in an effort known as I.M.A.G.E.
(Integrated Molecular Analysis of Genomes
and their Expression), cofounded by the
Livermore Human Genome Center. The aim
is a master set of mapped and sequenced
human cDNA, representing the expressed
parts of the human genome. By early 1996,
20

I.M.A.G.E. had distributed over 250,000
partial and complete cDNA clones, most of
them with one or both ends sequenced to
provide unique identifiers. These identifiers,
expressed sequence tags (ESTs), are usually
300–500 base pairs each. Twenty-five hundred genes have also been newly mapped as
part of this coordinated effort.
SHOTGUNS

AND TRANSPOSONS

Such advances as these, in both technology development and the assembly of
resource libraries, have brought much nearer
the day when “production sequencing” can
begin. A great deal of variety remains, however, in the approaches available to sequencing the human genome, and it is not yet clear
which will prove the most efficient and most
cost-effective way to read long stretches of
DNA over the next decade. One of the available choices, for example, is between “shotgun” and “directed” strategies. Another is
the degree of redundancy—that is, how
many times must a given strand be sequenced
to ensure acceptable confidence in the result?
Shotgun sequencing derives its name
from the randomly generated DNA fragments that are the objects of scrutiny. Many
copies of a single large clone are broken into
pieces of perhaps 1500 base pairs, either by
restriction enzymes or by physical shearing.
Each fragment is then separately cloned, and
a convenient portion of it sequenced. A computational assembly process then compares
the terminal sequences of the many fragments and, by finding overlaps that indicate neighboring fragments, constructs an
ordered library for the parent clone. The
members of this ordered library can then be
sequenced from end to end to yield a complete sequence for the parent. The statistics
involved in taking this approach require that
many copies of the original clone be
randomly fragmented, if no gaps are to be
tolerated in the final sequence. A benefit is
that the final sequence is highly reliable; the
main disadvantage is that the same sequence
must be done many times (in the many overlapping fragments). Nevertheless, shotgun
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sequencing has been the primary means for
generating most of the genomic sequence
data in public DNA databases. This includes
the longest contiguous fragment of sequenced human DNA, from the human
T-cell receptor beta region, of about 685,000
base pairs—a product of DOE-supported
work at the University of Washington.
The shotgun strategy is also being used
at the Genome Therapeutics Corporation and
The Institute for Genomic Research (TIGR),
as part of the DOE-supported Microbial
Genome Initiative. Genome Therapeutics
has sequenced 1.8 million base pairs of
Methanobacterium thermoautotrophicum, a bacterium important in energy production and
bioremediation, and TIGR has successfully
sequenced the complete genomes of three
free-living bacteria, Haemophilus influenzae
(1,830,137 base pairs; an effort supported
mostly by private funds), Mycoplasma genitalium (580,070 base pairs), and Methanococcus
jannaschii (1,739,933 base pairs).
The alternative to shotgun sequencing
is a directed approach, in which one seeks to
sequence the target clone from end to end
with a minimum of duplication. The essence
of this approach is embodied in a technique
known as primer walking. Starting at one end
of a single large fragment, one replicates a
stretch of DNA—say, 400 base pairs long—
that can be sequenced in one run. With the
sequence for this first segment in hand, the
next stretch of DNA, just overlapping the
first, is then tackled in the same way. In principle, one can thus “walk” the entire length of
the original clone. Unfortunately, this conceptually simple approach has been historically beset with disadvantages, mainly the
expense and inconvenience of customsynthesizing a primer as the necessary starting point for each sequencing step. The
widely automated Sanger sequencing method
involves a DNA replication step that must be
“primed” by a DNA fragment that is complementary to 15 to 20 base pairs of the strand to
be sequenced (see “Tools of the Trade,” pages
17–19). Until recently, making these primers
was an expensive and time-consuming business, but recent innovations have made

Large clone
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Select ordered
set of subclones

+ transposons ( )

3000 bp

Select subclones
to yield minimum
tiling path

Sequence regions
on both sides of
transposons

3000 bp

FIGURE 7. TAKING A DIRECTED APPROACH. One directed sequencing

strategy exploits a naturally occurring genetic element known as a transposon. The starting
point is an ordered set of subclones, each about 3000 base pairs long, derived from a much
larger clone (say, a YAC). For each subclone, a preparation is then made in which transposons
insert themselves randomly into the subclone—on average, one transposon in each 3000-basepair strand. The positions of the transposons are mapped, and a set of strands is selected such
that the insertion points are about 300 base pairs apart. Sequencing then proceeds in both
directions from the transposon insertion points, using the known transposon sequence as a
primer. The full set of overlapping regions yields the sequence for the entire subclone, and the
sequences of the full set of subclones yield the sequence for the larger original clone.

primer walking, and similar directed strategies, more and more economically feasible.
One way to deal with the primer bottleneck, for example, is to use sets of very short
fragments to prime the next sequencing step.
As an illustration, the four nucleotides (A, T,
C, and G) can be ordered in more than 68 billion ways to create an 18-base primer, an
imposing set of possibilities. But it is eminently practical to create a library of the 4096
possible 6-base primers. Three of these
“6-mers” can be matched to the end of the
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fragment to be sequenced, thus serving as an
18-base primer. This modular primer technology, developed at the Brookhaven
National Laboratory, is currently being
applied to Borrelia burgdorferi, the organism
that causes Lyme disease; a 34,000-base-pair
fragment has already been sequenced.
Another directed approach uses a naturally occurring genetic element called a transposon, which insinuates itself more or less randomly in longer DNA strands. This predilection for random insertion and the fact
that the transposon’s DNA sequence is well
known are the keys to the sequencing
strategy depicted schematically in Figure 7.
The largest clones are broken into smaller
subclones (each of about 3000 base pairs),
which then become the targets of the transposons. Multiple copies of each subclone are
exposed to the transposons, and reaction
conditions are controlled to
yield, on average, a single
insertion in each 3000-basepair strand. The individual
The completed
strands are then analyzed to
physical maps
yield, for each, the approximate position of the inserted
of chromosomes
transposon. By mapping
16 and 19 are
these positions, a “minimum
especially ripe
tiling path” can be determined for each subclone—
for large-scale
that is, a set of strands can be
sequencing.
identified whose transposon
insertions are roughly 300
base pairs apart. In this set
of strands, the region around
each transposon is then sequenced, using the
inserted transposons as starting points. The
known transposon sequence allows a single
primer to be used for sequencing the full set
of overlapping regions.
At the Lawrence Berkeley National
Laboratory, this technique has been used to
sequence over 1.5 million base pairs of DNA
on human chromosomes 5 and 20, as well as
over three million base pairs from the fruit fly
Drosophila melanogaster. On chromosome 5,
interest focuses on a region of three million
base pairs that is rich in growth factor and
receptor genes; whereas, on chromosome 20,
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Berkeley researchers are interested in a
region of about two million base pairs that is
implicated in 15 to 20 percent of all primary
breast carcinomas. As an example of the
kind of output these efforts produce, Figure
8 shows a stretch of sequence data from chromosome 5.
Researchers supported by the DOE at
the University of Utah are also pursuing the
use of directed sequencing. In addition, they
have developed a methodology for “multiplex” DNA sequencing, which offers a way
of increasing throughput with either shotgun or directed approaches. By attaching a
unique identifying sequence to each sequencing sample in a mixture of, say, 50 such samples, the entire mixture can be analyzed in a
single electrophoresis lane. The 50 samples
can be resolved sequentially by probing, first,
for bands containing the first identifier, then
for bands containing the second, and so
forth. In a similar way, multiplexing can also
be used for mapping. The Utah group is now
able to map almost 5000 transposons in a single experiment, and they are using multiplexing in concert with a directed sequencing
strategy to sequence the 1.8 million base
pairs of the thermophilic microbe Pyrococcus
furiosus and two important regions of human
chromosome 17.
The completed physical maps of chromosomes 16 and 19, with their extensive
coverage in many different kinds of cloning
vectors, are especially ripe for large-scale
sequencing. Los Alamos scientists have
therefore begun sequencing chromosome 16,
focusing special effort on locating the estimated 3000 expressed genes on that chromosome and using those sites as starting points
for directed genomic sequencing. A region of
60,000 base pairs has already been sequenced
around the adult polycystic kidney gene, and
good starts have been made in mapping other
genes. Interestingly, even random sequencing has led to the identification of gene DNA
in over 15 percent of the samples, confirming
the apparent high density of genes on this
chromosome. Between chromosome 16 and
the short arm of chromosome 5, another
Los Alamos target, the genome center there

Exploring the Genomic Landscape

has produced almost two million base pairs of
human DNA sequence.
A parallel effort is under way at
Livermore on chromosome 19 and other targeted genomic regions. Using a shotgun
approach, researchers there have completed
over 1.3 million bases of genomic sequence.
Initially, they are attacking two major regions
of chromosome 19: one of about two million
base pairs, containing several genes involved
in DNA repair and replication, and another
of approximately one million base pairs,
containing a kidney disease gene. The
Livermore scientists are making use of the
I.M.A.G.E. cDNA resource to sequence the
cDNA from these regions, along with the
associated segments of the genome. In addition, Livermore scientists have targeted
DNA repair gene regions throughout the
genome and, in many cases, have done comparative sequencing of these genes in other
Continues on p. 26

FIGURE 8. SEQUENCE DATA: THE FINAL PRODUCT. The ultimate
description of the genome, though only a prelude to full understanding, is the base-pair
sequence. This computer display shows results from the use of transposons at Berkeley.
The array of triangles represents the transposons inserted into a 3000-base-pair subclone;
the 11 selected by the computer to build a minimum tiling path are shown below the heaviest
black line. The subclone segments sequenced by using these 11 starting points are depicted
by the horizontal lines; the arrowheads indicate the sequencing directions. The expanded
region between bases 2042 and 2085 is covered by three sequencing reactions, which
produced the three traces at the bottom of the figure. Above the traces, the results are
summarized, together with a consensus sequence (just below the numbers).
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The Mighty Mouse
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he human genome is not so very
different from that of chimpanzees or
mice, and it even shares many common elements with the genome of the
lowly fruit fly. Obviously, the differences are critical, but so are the similarities. In
particular, genetic experiments on other organisms
can illuminate much that we could not otherwise
learn about homologous human genes—that
is, genes that are basically the same in the
two species.
In some cases, the connection between a
newly identified human gene and a known health
disorder can be quickly established. More often,
however, clear links between cloned genes and
human hereditary diseases or disease susceptibilities are extremely elusive. Diseases that are modified by other genetic predispositions, for example,
or by environment, diet, and lifestyle can be
exceedingly difficult to trace in human families.
The same holds for very rare diseases and for
genetic factors contributing to birth defects and
other developmental disorders. By contrast, disorders such as these can sometimes be followed
relatively easily in animal systems, where uniform
genetic backgrounds and controlled breeding
schemes can be used to avoid the variability that
often confounds human population studies. As a
consequence, researchers looking for clues to the
causes of many complex health problems are
focusing more and more attention on model animal systems.
Among such systems, which range in complexity from yeast and bacteria to mammals, the
most prominent is the mouse. Because of its small
size, high fertility rate, and experimental manipulability, the mouse offers great promise in studying
the genetic causes and pathological progress of
ailments, as well as understanding the genetic role
in disease susceptibility. In pursuing such studies,
the DOE is exploiting several resources, among
them the experimental mouse genetics facility at
the Oak Ridge National Laboratory. Initially

established for genetic risk assessment and toxicology studies, the Oak Ridge facility is one of the
world’s largest. Mutant strains there express a
variety of inherited developmental and health disorders, ranging from dwarfism and limb deformities to sickle cell anemia, atherosclerosis, and
unusual susceptibilities to cancer.
Most of these existing mutant strains have
arisen from random alterations of genes, caused
by the same processes that occur naturally in all
living populations. However, other, more directed
means of gene alteration are also available. Socalled transgenic methods, which have been
developed and refined over the past 15 years,
allow DNA sequences engineered in the
laboratory to be introduced directly into the
genomes of mouse embryos. The embryos are
subsequently transferred to a foster mother, where
they develop into mice carrying specifically
designed alterations in a particular gene. The differences in form, basic health, fertility, and
longevity produced by these “designer mutations”
then allow researchers to study the effects of
genetic defects that can mimic those found in
human patients. The payoff can be clues that aid
in the design of drugs and other treatments for the
human diseases.
The Human Genome Center at Berkeley is
using mice for similar purposes. In vivo libraries
of overlapping human genome fragments (each
100,000 to 1,000,000 base pairs long) are being
propagated in transgenic mice. The region of
chromosome 21 responsible for Down syndrome,
for example, is now almost fully represented in a
panel of transgenic mice. Such libraries have several uses. For example, the precise biochemical
means by which identified genes produce their
effects can be studied in detail, and new genes
can be recognized by analyzing the effects of
particular genome fragments on the transgenic
animals. In such ways, the promise of the massive
effort to map and sequence the human genome
can be translated into the kind of biological
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knowledge coveted by pharmaceutical designers
and medical researchers.
Adding to the potential value of mutant
mice as models for human genetic disease is growing evidence of similarities between mouse and
human genes. Indeed, practically every human
gene appears to have a counterpart in the mouse
genome. Furthermore, the related mouse and
human genes often share very similar DNA
sequences and the same basic biological function.
If we imagine that the 23 pairs of human chromosomes were shattered into smaller blocks—to yield
a total of, say, 150 pieces, ranging in size from
very small bits containing just a few genes to
whole chromosome arms—those pieces could be
reassembled to produce a serviceable model of the
mouse genome. This mouse genome jigsaw puzzle is shown to the right. Thanks to this mousehuman genomic homology, a newly located gene
on a human chromosome can often lead to a confident prediction of where a closely related gene
will be found in the mouse—and vice versa.
Thus, a crippling heritable muscle disorder
in mice maps to a location on the mouse X chromosome that is closely analogous to the map location for the X-linked human Duchenne muscular
dystrophy gene (DMD). Indeed, we now know
that these two similar diseases are caused by the
mouse and human versions of the same gene.
Although mutations in the mouse mdx gene produce a muscle disease that is less severe than the
heartbreaking, fatal disease resulting from the
DMD mutation in humans, the two genes produce
proteins that function in very similar ways and that
are clearly required for normal muscle development and function in the corresponding species.
Likewise, the discovery of a mouse gene associated with pigmentation, reproductive, and blood
cell defects was the crucial key to uncovering the
basis for a human disease known as the piebald
trait. Owing to such close human-mouse relationships as these, together with the benefits of transgenic technologies, the mouse offers enormous
potential in identifying new human genes, deciphering their complex functions, and even treating
genetic diseases. ❖
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OF MICE AND MEN. The genetic similarity (or homology) of superficially dissimilar

species is amply demonstrated here. The full complement of human chromosomes can be cut,
schematically at least, into about 150 pieces (only about 100 are large enough to appear in
this illustration), then reassembled into a reasonable approximation of the mouse genome.
The colors of the mouse chromosomes and the numbers alongside indicate the human chromosomes containing homologous segments. This piecewise similarity between the mouse and
human genomes means that insights into mouse genetics are likely to illuminate human
genetics as well.
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species, especially the mouse. Such comparative sequencing has identified conserved
sequence elements that might act as regulatory
regions for these genes and has also assisted in
the identification of gene function (see “The
Mighty Mouse,” pages 24–25).
HOW

GOOD IS GOOD ENOUGH?

The goal of most sequencing to date
has been to guarantee an error rate below
1 in 10,000, sometimes even 1 in 100,000.
However, the difference between one human
being and another is more like one base pair in
five hundred, so most researchers now agree
that one error in a thousand is a more reasonable standard. To assure a higher level of confidence, and perhaps to uncover important
individual differences, the most biologically or
medically important regions would still be
sequenced more exhaustively, but using this
lowered standard would greatly reduce the cost
of acquiring sequence data for the bulk of
human DNA.
With this philosophy in mind, Los
Alamos scientists have begun a project to
determine the cost and throughput of a lowredundancy sequencing strategy known as
sample sequencing (SASE, or “sassy”). Clones
are selected from the high-resolution Los
Alamos cosmid map, then physically broken
into 3000-base-pair subclones—much as in
other sequencing approaches. In contrast to,
say, shotgun sequencing, though, only a small
random set of the subclones is then selected for
sequencing. Sequence fragments already
known—end sequences, sequence-tagged sites,
and so forth—are used as the starting points.
The result is sequence coverage for about 70
percent of the original cosmid clone, enough to
allow identification of genes and ESTs, thus
pinpointing the most critical targets for later,
more thorough sequencing efforts. Further,
the SASE-derived sequences provide enough
information for researchers elsewhere to pursue just such comprehensive efforts, using
whole genomic DNA. In addition, the cost of
SASE sequencing is only one-tenth the cost of
obtaining a complete sequence, and a genomic
region can be “sampled” ten times as fast.
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As the first major target of SASE analysis, Los Alamos scientists chose a cosmid
contig of four million base pairs at the end
(the telomere) of the short arm of chromosome
16. By early 1996, over 1.4 million base pairs
had been sequenced, and a gene, EST, or suspected coding region had been located on
every cosmid sampled.
In addition, Los Alamos is building on
the SASE effort by using SASE sequence
data as the basis for an efficient primer walking strategy for detailed genomic sequencing.
The first application of this strategy, to a
telomeric region on the long arm of chromosome 7, proved to be as efficient as typical
shotgun sequencing, but it required only
two- to threefold redundancy to produce
a complete sequence, in contrast to the
seven- to tenfold redundancy required in
shotgun approaches. The resulting 230,000base-pair sequence is the second-longest
stretch of contiguous human DNA sequence
ever produced.
❖

In a sense, though, even a complete genome
sequence—the ultimate physical map—is
only a start in understanding the human
genome. The deepest mystery is how the
potential of 100,000 genes is regulated and
controlled, how blood cells and brain cells are
able to perform their very different functions
with the same genetic program, and how
these and countless other cell types arise in
the first place from an single undifferentiated
egg cell. A first step toward solving these
subtle mysteries, though, is a more complete
physical picture of the master molecules that
lie at the heart of it all.

Beyond Biology
I N S T R U M E N TAT I O N

F

ROM THE START,

A N D

it has been clear
that the Human Genome Project
would require advanced instrumentation and automation if its
mapping and sequencing goals
were to be met. And here, especially, the
DOE’s engineering infrastructure and tradition of instrumentation development have
been crucial contributors to the international
effort. Significant DOE resources have been
committed to innovations in instrumentation,
ranging from straightforward applications of
automation to improve the speed and efficiency of conventional laboratory protocols
(see, for example, Figure 9a) to the development of technologies on the cutting edge—
technologies that might potentially increase
mapping and sequencing efficiencies by
orders of magnitude.
On the first of these fronts, genome
researchers are seeing significant improvements in the rate, efficiency, and economy of
large-scale mapping and sequencing efforts
as a result of improved laboratory automation tools. In many cases, commercial robots
have simply been mechanically reconfigured
and reprogrammed to perform repetitive
tasks, including the replication of large clone
libraries, the pooling of libraries as a prelude
to various assays, and the arraying of clone
libraries for hybridization studies. In other
cases, custom-designed instruments have
proved more efficient. A notable illustration is the world’s fastest cell and chromosome sorter, developed at Livermore and
now being commercialized, which is used
to sort human chromosomes for chromosome-specific libraries. Other examples

I N F O R M AT I C S

include a high-speed, robotics-compatible thermal cycler developed at Berkeley,
which greatly accelerates PCR amplifications, and instruments developed at Utah
for automated hybridization in multiplex
sequencing schemes.
SMALLER

IS BETTER—AND

OTHER DEVELOPMENTS

Beyond “mere” automation are efforts
aimed at more fundamental enhancements
of established techniques. In particular, a
number of DOE-supported efforts aim at
improved versions of the automated gelbased Sanger sequencing technique. For example, in place of
the conventional slab gels, ultraThe project will
thin gels, less than 0.1 millimeter thick, can be used to obtain
require advanced
400 bases of sequence from each
instrumentation
lane in a hour’s run, a fivefold
improvement in throughput
and automation
over conventional systems.
if its goals are
Even faster speedups are seen
when arrays of 0.1-millimeter
to be met.
capillaries are used as the separation medium. Both of these
approaches exploit higher electric field strengths to increase DNA mobility
and to reduce analysis times. And Livermore
scientists are looking beyond even capillaries, to sequencing arrays of rigid glass
microchannels, supplemented by automated
gel and sample loading.
The capillary approach is especially
ripe for further development. Challenges
include providing uniform excitation over
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FIGURE 9. FASTER, SMALLER, CHEAPER. Innovations in automation and instrumentation promise
not only the virtues of speed, reduced size, and economy, but also a reduction in the drudgery of repetition.
The examples shown here illustrate three technological advances. (a) One of the tediously repetitive tasks of
molecular genetics is transferring randomly plated bacterial colonies, as seen in the foreground video image, to
microtitre array plates. An automated colony picker robot developed at Berkeley, then modified at Livermore,
can pick 1000 colonies per hour and place them in array plates such as the one being examined here by a
Livermore researcher. (b) Photolithographic techniques inspired by the semiconductor industry are the basis for
preparing high-density oligonucleotide arrays. Shown here is a 1.28 x 1.28–cm array of more than 10,000
different nucleotide sequences (probes), which was then incubated with a cloned fragment (the target) from the
genome of the HIV-1 virus. If the fluorescently labeled target contained a region complementary to a sequence in
the array, the target hybridized with the probe, the extent of the hybridization depending on the extent of the
match. This false-color image depicts different levels of detected fluorescence from the bound target fragments.
Techniques such as this may ultimately be used in sequencing applications, as well as in exploring genetic diversity,
probing for mutations, and detecting specific pathogens. Photo courtesy of Affymetrix. (c) Sequencing based on
the detection of fluorescence from single molecules is being pursued at Los Alamos. The strand of DNA to be
sequenced is replicated using nucleotides linked to a fluorescent tag—a different tag for each of the four
nucleotides. The tagged strand is then attached to a polystyrene bead suspended in a flowing stream of water,
and the nucleotides are enzymatically detached, one at a time. Laser-excited fluorescence then yields the
nucleotide sequence, base by base. Much development remains to be done on this technique, but success promises
a cheaper, faster approach to sequencing, one that might be applicable to intact cosmid clones 40,000 bases long.
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arrays of 50 to 100 capillaries and then
efficiently detecting the fluorescence emitted
by labeled samples. Technologies under
investigation include fiber-optic arrays, scanning confocal microscopy, and cooled CCD
cameras. Some of this effort has already
been transferred to the private sector, and
tenfold improvements in speed, economy,
and efficiency are projected in future
commercial instruments.
The move toward miniaturization is
afoot elsewhere as well. Building on experiences in the electronics industry, several
DOE-supported groups are exploring ways
to adapt high-resolution photolithographic
methods to the manipulation of minuscule
quantities of biological reagents, followed by
assays performed on the same “chip.”
Current thrusts of this “nanotechnology”
approach include the design of microscopic
electrophoresis systems and ultrasmall-volume, high-speed thermal cycling systems for
PCR. A miniaturized, computer-controlled
PCR device under development at Livermore
operates on 9-volt batteries and might ultimately lead to arrays of thousands of individually controlled micro-PCR chambers.
Another miniaturization effort aims at
the fabrication of high-density combinatorial
arrays of custom oligomers (short chains of
nucleotides), which would make feasible
large-scale hybridization assays, including
sequencing by hybridization. This innovative technique uses short oligomers that
pair up with corresponding sequences of
DNA. The oligomers are placed on an array
by a process similar to that of making silicon
chips for electronics. Successful matches
between oligomers and genomic DNA are
then detected by fluorescence, and the application of sophisticated statistical analyses
reassembles the target sequence. This same
technology has already been used for genetic
screening and cDNA fingerprinting. Figure
9b illustrates a DOE-supported application
of high-density oligonucleotide arrays to the
detection of mutations in the HIV-1 genome.
Similar approaches can be envisioned to
understand differences in patterns of gene
expression: Which genes are active (which

are producing mRNA) in which cells? Which
are active at different times during an organism’s development? Which are active, or inactive, in disease?
Sequencing by hybridization is only one
of several forward-looking ideas for revolutionizing sequencing technology. In spite of
continuing improvements to sequencers based
on the classic methods, it is
nonetheless desirable to explore
altogether new approaches, with
In spite of
an eye to simplifying sample
improvements to
preparation, reducing measurement times, increasing the length
sequencers based
of the strands that can be analyzed
on the classic
in a single run, and facilitating
interpretation of the results. Over
methods, it is
the course of the past few years,
nonetheless
several alternative approaches to
direct sequencing have been
desirable to
explored, including atomic-resoluexplore altogether
tion molecular scanning, singlenew approaches.
molecule detection of individual
bases, and mass spectrometry of
DNA fragments.
All of these alternatives look promising
in the long term, but mass spectrometry has
perhaps demonstrated the greatest near-term
potential. Mass spectrometry measures the
masses of ionized DNA fragments by recording their time-of-flight in vacuum. It would
therefore replace traditional gel electrophoresis as the last step in a conventional sequencing scheme. Routine application of this technique still lies in the future, but fragments of
up to 500 bases have been analyzed, and practical systems based on high-resolution mass
separations of DNA fragments of fewer than
100 bases are currently being developed at
several universities and national laboratories.
Another innovative sequencing method
is under investigation at Los Alamos. As
depicted in Figure 9c, each of the four bases
(A, T, C, G) in a single strand of DNA
receives a different fluorescent label, then the
bases are enzymatically detached, one at a
time. The characteristic fluorescence is
detected by a laser system, thereby yielding
the sequence, base by base. This approach is
beset by major technical challenges, and direct
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FIGURE 10. GENE HUNTS. Genes, the regions that actually code for proteins, constitute only a small fraction, perhaps
10%, of the human genome. Thus, even with sequence in hand, finding the genes is yet another daunting step away. One tool
developed to help in the hunt is GRAIL, a computer program developed at Oak Ridge that uses heuristics based on existing data,
together with artificial neural networks, to identify likely genes. Coding and noncoding regions of the genome differ in many subtle
respects—for example, the frequency with which certain short sequences appear. Further, particular landmarks are known to characterize the boundaries of many genes. In the example shown here, GRAIL has searched for likely genes in both strands of a 3583-basepair sequence. The results are shown at the upper left. The upper white trace indicates five possible exons (coding regions within a
single gene) in one strand, whereas the lower white trace suggests two possible exons in the other strand. However, the lower trace
scores worse on other tests, leading to a candidate set of exons shown by the five green rectangles. By refining this set further, GRAIL
then produces the final gene model shown in light blue. The lower part of the figure zeros in on the end of the candidate exon outlined
in yellow, thus providing a detailed look at one of the differences between the preliminary and final models. The sequence is shown in
violet, together with the amino acids it codes for, in yellow. The preliminary model thus begins with the sequence GTCGCA. . . , which
codes for the amino acids valine and alanine. In fact, though, almost all genes begin with the amino acid methionine, a feature of the
final gene model. At the upper right, GRAIL displays the results of a database search for sequences similar to the final five-exon gene
model. Close matches were found among species as diverse as soybean and the nematode Caenorhabditis elegans.

sequencing has not yet been achieved. But
the potential benefits are great, and much of
the instrumentation for sensitive detection of
fluorescence signals has already proved
useful for molecular sizing in mapping
applications.
DEALING

W I T H T H E D ATA

Among the less visible challenges of the
Human Genome Project is the daunting
prospect of coping with all the data that success implies. Appropriate information systems are needed not only during data acquisition, but also for sophisticated data analysis
and for the management and public distribution of unprecedented quantities of biological
information. Further, because much of the
challenge is interpreting genomic data and
making the results available for scientific and
technological applications, the challenge
extends not just to the Human Genome
30

Project, but also to the microbial genome
program and to public- and private-sector
programs focused on areas such as health
effects, structural biology, and environmental
remediation. Efforts in all these areas are the
mandate of the DOE genome informatics
program, whose products are already widely
used in genome laboratories, general molecular biology and medical laboratories, biotechnology companies, and biopharmaceutical
companies around the world.
The roles of laboratory data acquisition
and management systems include the construction of genetic and physical maps, DNA
sequencing, and gene expression analysis.
These systems typically comprise databases
for tracking biological materials and experimental procedures, software for controlling
robots or other automated systems, and
software for acquiring laboratory data and
presenting it in useful form. Among such
systems are physical mapping databases
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developed at Livermore and Los Alamos,
robot control software developed at Berkeley
and Livermore, and DNA sequence assembly
software developed at the University of
Arizona. These systems are the keys to efficient, cost-effective data production in both
DOE laboratories and the many other laboratories that use them.
The interpretation of map and sequence
data is the job of data analysis systems.
These systems typically include task-specific
computational engines, together with graphics and user-friendly interfaces that invite
their use by biologists and other non–computer scientists. The genome informatics
program is the world leader in developing
automated systems for identifying genes
in DNA sequence data from humans and
other organisms, supporting efforts at Oak
Ridge National Laboratory and elsewhere.
The Oak Ridge–developed GRAIL system,
illustrated in Figure 10, is a world-standard
gene identification tool. In 1995 alone, more
than 180 million base pairs of DNA were
analyzed with GRAIL.
A third area of informatics reflects, in a
sense, the ultimate product of the Human
Genome Project—information readily available to the scientific and lay communities.

Public resource databases must provide data
and interpretive analyses to a worldwide
research and development community. As
this community of researchers expands and
as the quantity of data grows, the challenges of maintaining accessible and useful
databases likewise increase. For example, it
is critical to develop scientific databases that
“interoperate,” sharing data and protocols so
that users can expect answers to complex
questions that demand information from geographically distributed data resources. As
the genome project continues to provide data
that interlink structural and functional biochemistry, molecular, cellular, and developmental biology, physiology and medicine, and
environmental science, such interoperable
databases will be the critical resources
for both research and technology development. The DOE genome informatics program is crucial to the multiagency effort to
develop just such databases. Systems now
in place include the Genome Database of
human genome map data at Johns Hopkins
University, the Genome Sequence DataBase
at the National Center for Genome
Resources in Santa Fe, and the Molecular
Structure Database at Brookhaven National
Laboratory.
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Ethical, Legal, and
Social Implications
AN

ESSENTIAL

T

DIMENSION

HE HUMAN GENOME PROJECT is
rich with promise, but also
fraught with social implications.
We expect to learn the underlying causes of thousands of
genetic diseases, including sickle cell anemia,
Tay-Sachs disease, Huntington disease,
myotonic dystrophy, cystic fibrosis, and
many forms of cancer—and thus to predict
the likelihood of their occurrence in any individual. Likewise, genetic information might
be used to predict sensitivities to various
industrial or environmental agents. The dangers of misuse and the potential threats to
personal privacy are not to
be taken lightly.
In recognition of these
Both the
important issues, both the
DOE and the National
DOE and the
Institutes of Health devote a
NIH devote a
portion of their resources to
portion of their
studies of the ethical, legal,
and social implications
resources to
(ELSI) of human genome
studies of ethical,
research. Perhaps the most
critical of social issues are
legal, and social
the questions of privacy and
implications.
fair use of genetic information. Most observers agree
that personal knowledge of
genetic susceptibility can be
expected to serve us well, opening the door to
more accurate diagnoses, preventive intervention, intensified screening, lifestyle
changes, and early and effective treatment.
But such knowledge has another side, too:
the risk of anxiety, unwelcome changes in
personal relationships, and the danger of
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stigmatization. Consider, for example, the
impact of information that is likely to be
incomplete and indeterminate (say, an indication of a 25 percent increase in the risk of
cancer). And further, if handled carelessly,
genetic information could threaten us with
discrimination by potential employers and
insurers. Other issues are perhaps less
immediate than these personal concerns, but
they are no less challenging. How, for example, are the “products” of the Human
Genome Project to be patented and commercialized? How are the judicial, medical,
and educational communities—not to mention the public at large—to be effectively
educated about genetic research and its
implications?
To confront all these issues, the NIHDOE Joint Working Group on Ethical,
Legal, and Social Implications of Human
Genome Research was created in 1990 to
coordinate ELSI policy and research
between the two agencies. One focus of
DOE activity has been to foster educational
programs aimed both at private citizens and
at policy-makers and educators. Fruits of
these efforts include radio and television documentaries, high school curricula and other
educational material, and science museum
displays. In addition, the DOE has concentrated on issues associated with privacy and
the confidentiality of genetic information, on
workplace and commercialization issues
(especially screening for susceptibilities to
environmental or workplace agents), and on
the implications of research findings regarding the interactions among multiple genes
and environmental influences.

Ethical, Legal, and Social Implications

tives and reasonable arguments, even precious rights, exist on opposing sides of every
issue. It is a balance that must be sought.
Accordingly, further study is needed, as well
as continuing efforts to promote public awareness and understanding, as we strive to define
policies for the intelligent use of the profound
knowledge we seek about ourselves.

Whereas the issues raised by modern
genome research are among the most challenging we face, they are not unprecedented.
Issues of privacy, knotty questions of how
knowledge is to be commercialized, problems
of dealing with probabilistic risks, and the
imperatives of education have all been confronted before. As usual, defensible perspec-

❖

T

was the age
of da Gama, Columbus, and
Magellan, an era when European
civilization reached out to the
Far East and thus filled many of
the voids in its map of the world. But in a
larger sense, we have never ceased from our
exploration and discovery. Science has been
unstinting over the ages in its efforts to
complete our intellectual picture of the universe. In this century, our explorations have
extended from the subatomic to the cosmic, as
we have mapped the heavens to their farthest
reaches and charted the properties of the
most fleeting elementary particles. Nor have
we neglected to look inward, seeking, as it
were, to define the topography of the human
body. Beginning with the first modern
anatomical studies in the sixteenth century,
we have added dramatically to our picture of
human anatomy, physiology, and biochemistry. The Human Genome Project is thus the
next stage in an epic voyage of discovery—a
voyage that will bring us to a profound understanding of human biology.
In an important way, though, the
genome project is very different from many of
our exploratory adventures. It is spurred by
a conviction of practical value, a certainty
that human benefits will follow in the wake of
success. The product of the Human Genome
Project will be an enormously rich biological
HE AGE OF DISCOVERY

database, the key to tracking down every
human gene—and thus to unveiling, and
eventually to subverting, the causes of thousands of human diseases. The sequence of
our genome will ultimately allow us to unlock
the secrets of life’s processes, the biochemical
underpinnings of our senses and our memory,
our development and our aging, our similarities and our differences.
It has further been said that the Human
Genome Project is guaranteed to succeed: Its
goal is nothing more assuming than a
sequence of three billion characters. And we
have a very good idea of how to read those
characters. Unlike perilous voyages or
searches for unknown subatomic particles,
this venture is assured of its goal. But
beyond a detailed picture of human DNA, no
one can predict the form success will take.
The genome project itself offers no promises
of cancer cures or quick fixes for Alzheimer’s
disease, no detailed understanding of genius
or schizophrenia. But if we are ever to
uncover the mysteries of carcinogenesis, if
we are ever to know how biochemistry contributes to mental illness and dementia, if we
ever hope to really understand the processes
of growth and development, we must first
have a detailed map of the genetic landscape.
That’s what the Human Genome Project
promises. In a way, it’s a rather prosaic step,
but what lies beyond is breathtaking.
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The World Wide Web offers the easiest path to current news about the Human Genome Project.
Good places to start include the following:
• DOE Human Genome Program—http://www.er.doe.gov/production/oher/hug_top.html
• NIH National Center for Human Genome Research—http://www.nchgr.nih.gov
• Human Genome Management Information System at Oak Ridge National Laboratory—
http://www.ornl.gov/TechResources/Human_Genome/home.html
• Lawrence Berkeley National Laboratory Human Genome Center—
http://www-hgc.lbl.gov/GenomeHome.html
• Lawrence Livermore National Laboratory Human Genome Center—
http://www-bio.llnl.gov/bbrp/genome/genome.html
• Los Alamos National Laboratory Center for Human Genome Studies—
http://www-ls.lanl.gov/LSwelcome.html
• The Genome Database at Johns Hopkins University School of Medicine—
http://gdbwww.gdb.org/
• The National Center for Genome Resources—http://www.ncgr.org/
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